Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Assets (2020 - 2025)

Caribou Biosciences has reported Assets over the past 6 years, most recently at $175.4 million for Q4 2025.

  • Quarterly Assets fell 44.03% to $175.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.4 million through Dec 2025, down 44.03% year-over-year, with the annual reading at $175.4 million for FY2025, 44.03% down from the prior year.
  • Assets was $175.4 million for Q4 2025 at Caribou Biosciences, down from $195.0 million in the prior quarter.
  • Over five years, Assets peaked at $462.0 million in Q3 2021 and troughed at $158.4 million in Q2 2021.
  • The 5-year median for Assets is $372.9 million (2024), against an average of $346.9 million.
  • Year-over-year, Assets skyrocketed 1127.2% in 2021 and then plummeted 44.03% in 2025.
  • A 5-year view of Assets shows it stood at $442.4 million in 2021, then dropped by 15.51% to $373.8 million in 2022, then rose by 15.64% to $432.2 million in 2023, then dropped by 27.51% to $313.3 million in 2024, then plummeted by 44.03% to $175.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Assets are $175.4 million (Q4 2025), $195.0 million (Q3 2025), and $220.9 million (Q2 2025).